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M protein is amajor surface component ofgroup A streptococci, and more than
80 distinct serological types exist. Antigenic variability resides in the NH2-terminal
distal portion ofthe fibrillarMprotein molecule, whereas the COOH-terminal half
is highly conserved among different M serotypes (1, 2). With few exceptions, only
serum IgGdirected to the antigenically variable portion ofMprotein initiates opso-
nization and phagocytosis ofstreptococci bypolymorphonuclearleukocytes (3). The
presence oftype-specific antibodies in serum correlates with protection against group
A streptococcal pharyngitis in humans (4, 5), which involves inflammation of the
nasopharyngeal mucosa and underlyingtissue. Alternatively, this organism can col-
onize the pharyngeal mucosa leading to a carrier state without clinical signs. The
carrier state can persist after the development oftype-specific serum antibodies (5,
6), suggesting that opsonic IgG is protective only after streptococcal infection (i.e.,
pharyngitis) is established.
While humans are considered to be theprimary reservoir forgroup A streptococci,
natural infection has been reported to occur in mice with the M50 serotype (7, 8).
Streptococci administered intranasally to mice can cause death by colonizing and
subsequently invading the mucosal barrier and disseminating to systemic sites. Im-
munological protection against lethal streptococcal infection by the intranasal route
might occur at either a mucosal or nonmucosal (underlying tissue, systemic) site.
Secretory IgA (sIgA) can protect mucosal surfaces from colonization by pathogenic
bacteria, and the effector functions ofsIgA differ from those ofserum-derived Igs.
We investigated therole ofanti-M protein-specific sIgA in protecting against strep-
tococcalinfection at the mucosa. Usinga mouse model, live streptococci were mixed
with affinity-purified antibodies and were administered intranasally. The dataindi-
cate that passively acquired anti-M protein sIgA given by the intranasal route pro-
tected mice against streptococcal infection, whereas opsonic serum Ig administered
intranasally was without effect. The results suggestthat sIgA can protect atthe mucosa,
and may preclude the need for opsonic IgG in preventing streptococcal infection.
Materials and Methods
Purification ofAntibodies.
￿
Pooled human saliva was clarifiedby ultracentrifugation(50,000
g, 2 h), passed over jacalin immobilized on agarose (Pierce Chemical Co., Rockford, IL),
eluted with 0.1 Mmelibiose, dialyzed, and concentrated. Antibodies directed to type 6 M
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protein (M6) were purified from whole serum (pooled human and hyperimmune rabbit) or
from salivary IgA by passage over gluterdialdehyde glass beads (Boehringer Mannheim Bio-
chemicals, Indianapolis, IN) derivatized with M6 protein (ColiM6, the product of the M6
gene cloned in Escherichia colt) (9), eluted with 0.1 M glycine, pH 2 .1, dialyzed, concentrated,
and adjusted to 1.5% BSA/0.03 M Hepes, pH 7 .4. Affinity purification on the M6 column
resulted in absorption of >90% ofthe anti-M6 protein immunoreactivity. The opsonic mAb
3B8 (10) was added to the anti-M6 serum Ig preparation at a final concentration of400 wg/ml
to further maximize the array of immunospecificities in this fraction. The final volume of
purified antibodies to M6 protein was concentrated 200-fold over unfractionated saliva for
sIgA, and threefold over whole serum for serum Igs.
ELISA.
￿
Microtiter wells were coated with 0.5 (Fig. 1 A) or 1.0 Ag/ml (Fig. 1 B) of ColiM6
protein. For competition ELISA (11), antibodies were preincubated (18 h, 4°C) with decreasing
concentrations of ColiM6 starting at a 50-mol excess relative to the amount used to coat wells.
A fixed concentration (1 :200 dilution) ofthe two antibody preparations (anti-M6 sera Ig and
sIgA) was chosen for competitive inhibition because this dilution gave a level of immunoreac-
tivity for each component (human, rabbit, mouse) that could be measured by competition.
All incubations containing antibodies were performed in 0.01 M sodium phosphate, pH 7.4/0.5
M NaCI/0.25% Brij . Secondary antibodies were conjugated with alkaline-phosphatase (Sigma
Chemical Co., St. Louis, MO), and immunoreactivity was detected at A405 using p-
nitrophenyl phosphate substrate (to establish the endpoint titer in Fig. 1 B, the developing
time was 60 min at 37°C).
Bactericidal Assay.
￿
Purified antibody or whole serum (100 Al) was added to type 6 strep-
tococcal strain 543/192 in Todd-Hewitt broth (100 ul) and whole heparinized blood (400 g1)
from a nonopsonic donor. The mixture was rotated for 3 h at 37°C, a portion was plated
onto proteose peptone agar, and viable organisms were enumerated by measuring CFU (12).
Mouse Protection Assay.
￿
Type 6 streptococci (strain 543/192) were grown to mid-log phase
in Todd-Hewitt broth, and each animal received (intranasally) between 5 x 104 and 5 x 105
CFU (depending on the experiment) suspended in 20 wl of control buffer or purified M6
protein-specific antibody. The time elapsed between suspension of streptococci in antibody
or control buffer, and administration to mice, was no longer than 10-15 min. Intranasal in-
oculations were delivered to the nares of unanesthetized mice through a Hamilton syringe.
Female, BALB/c nu/+ mice (Harlan Sprague Dawley, Inc., Indianapolis, IN) were 4-6 wk old.
Ig Binding Assay.
￿
The binding of radioiodinated IgA and IgG to mid-log phase bacteria
suspended in 1 .5% BSA-saline was performed as previously described (13). Purified human
myeloma IgA (ICN ImmunoBiologicals, Lisle, IL) and human sera IgG (CooperBiomedical,
Inc., West Chester, PA) were labeled with 1211 using Iodo-beads (Pierce Chemical Company).
Results and Discussion
Pooled human salivary IgA was isolated by binding to jacalin, a lectin with specificity
for human IgAl (14). Antibodies directed to M6 protein were purified from jacalin-
released sIgA or from whole serum (pooled human and rabbit) by passage over an
immunoabsorbent column of the native M6 molecule, which contains both type-
specific and conserved immunodeterminants. Saliva or serum was pooled from sev-
eral sources to compensate for individual responses to different M protein epitopes.
The M6-specific antibodies from hyperimmune rabbit serum and mAb to M6 pro-
tein were included in the serum Ig preparation to further maximize the array of
immunospecificities in this fraction .
The immunoreactivity of the two antibody preparations was evaluated by ELISA.
The anti-M6 sera Ig contains antibodies from three species, each of which requires
a distinct secondary antibody for detection. Therefore, to evaluate the relative im-
munoreactivities of anti-M6 sIgA and sera Ig, a competition ELISA using a fixed
antibody concentration and ColiM6 as the inhibitor was performed (Fig. 1 A). The
quantity ofM6 protein required for 50% inhibition of each anti-M6 serum Ig com-A
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TABLE I
ponent was at least 32-fold greater than that required to inhibit sIgA. Direct binding
of sIgA to M6 protein was compared with the human component of the sera Ig prep-
aration by using anti-light chain secondary antibody (Fig. 1 B) . The endpoint titer
(highest dilution reciprocal of antibody giving A405 equal to 1 .0) of human sera Ig
exceeded that of anti-M6 salivary IgA by N28-fold. The quantity of IgG present
in the sIgA preparation was determined by capture ELISA and was estimated to
be <1.0% (data not shown).
The bactericidal assay was used to determine the opsonic activity of the antibodies
used in passive immunization (Table I). When type 6 streptococci were rotated in
the blood of a donor who lacked antibodies specific for the M6 molecule, the or-
ganisms evaded phagocytosis and grew freely (control). Purified anti-M6 serum Ig
displayed opsonic activity, and the organisms did not survive. In contrast, purified
anti-M6 sIgA failed to promote phagocytosis; one reason for this behavior may be
due to the inability of sIgA to fix complement efficiently (15). In addition, the op-
sonic activity of pooled sera from those individuals who served as sources for the
purified sIgA and serum Ig was measured. Sera from both the serumIg and salivary
IgA sources was effective in opsonizing type 6 streptococci.
Bactericidal Activity of Antibody Used in Passive Immunization
FIGURE 1 .
￿
Immunoreactivity of antibody used in passive protection. (A) Competition ELISA
with M6 protein. Percent inhibition of binding of purified anti-M6 sera Ig detected with sec-
ondary antibodies to human light chain (X and Ic) (A), rabbit IgG (0), and mouse IgG (0),
and ofpurified anti-M6 sIgA detected with anti-human light chain (O). (B) ELISA measuring
direct binding to M6 protein by anti-M6 sIgA (O) and sera Ig (A) detected with anti-human
light chain .
Colony forming units*
Addition of:
￿
Inoculum: 50
￿
23
Sera (nonopsonic control)
￿
8,624
￿
4,914
Sera (from sera Ig source)
￿
<10
￿
<10
Sera (from sIgA source)
￿
49
￿
14
Purified anti-M6 sera Ig
￿
35
￿
<10
Purified anti-M6 sIgA
￿
>10,000
￿
3,640
* Expressed as total colony forming units.1948
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FIGURE 2 . Passive protection of mice
against streptococcal challenge (in-
tranasally) by anti-M6 protein salivary
IgA . Mice received live organisms sus-
pended in 1.5% BSA/0.03 M Hepes, pH
7.4 (1], control), anti-M6 serum Ig (10),
or anti-M6 sIgA (N) . Three separate ex-
periments were performed, and a total of
20 animals are represented per group. The
number of mice surviving streptococcal
challenge was recorded at 12-h intervals.
Significant difference (*) between sIgA and
control according to x2 analysis (p < 0.05) .
Fig . 2 shows that intranasal administration ofanti-M6 protein salivary IgA had
a significant blocking effect on mouse mortality resulting from intranasal challenge
with type 6 streptococci . Beginning at 60 h post-challenge, animals given anti-M6
sIgA displayed a higher rate of survival than the control group, which had received
streptococci suspended in 1.5% BSA only. Between 96 and 132 h post-challenge,
the difference between these two groups was significant . Furthermore, the number
of survivors in the sIgA group exceeded the control at every time point in each of
three independent experiments (data not shown) . However, to the contrary, mice
given the anti-M6 serum Ig preparation exhibited mortality rates nearly identical
to the control group .
In a separate set oftwo experiments, antibodies derived from a singlehuman donor
protected in a manner similar to antibodies from pooled sources . At 7 d after strep-
tococcal challenge, 75% (15/20) of the mice given anti-M6 sIgA (intranasally) from
the single donor had survived, compared with 35% (7/20) given anti-M6 sera Ig
and 40% (8/20) of the 1 .5% BSA control group . Thus, despite its lowerimmunoreac-
tivity (Fig . 1) and lack of opsonic activity (Table I), anti-M6 salivary IgA significantly
inhibited streptococcal infection at the mucosal level, whereas serum-derived anti-M6
antibodies were without effect at this site . Furthermore, antibodies derived from ei-
ther pooled sources or a single donor had similar patterns of protective ability .
Many isolates of streptococci and staphylococci possess surface receptors for IgA
TABLE II
Lack of Nonimmune Binding of Ig by Type 6 Streptococci
* Average mean and SD of percent radioactivity bound to organisms measured
in triplicate .
" Group A streptococci (S43/192), group B streptococci (H36B-5 and 090R),
and S. aureus (Cowan I) .
Organism l
Percent bound*
( 125I)-IgA ( 1`1)-I gG
S43/192 3.63 ± 0.22 1 .66 ± 0.28
H36B-5 50.91 ± 2.02 1 .65 ± 0.09
090R 5.30 ± 0.45 ND
Cowan I ND 53.82 ± 2.76BESSEN AND FISCHETTI BRIEF DEFINITIVE REPORT
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and IgG (13). To establish that strain 543/192 did not interact with Igs by a nonim-
mune mechanism, the binding of radioiodinated IgA and IgG to the surface of 543/192
streptococci was measured (Table II). Group B streptococci (GBS) that express an
IgA binding-protein (H36B-5), and Staphylococcus aureus (Cowan I strain) served as
positive controls for IgA and IgG binding, respectively. Strain 543/192 bound radio-
labeled IgA at low levels that were comparable with that bound by a GBS strain
(090R) that lacks the IgA binding protein. The data indicate that the type 6 strep-
tococcal strain used for challenge in this study fails to bind either IgA or IgG by
a nonimmune mechanism.
It does not appear that passively acquired serum Igs were used at the mucosa
by a mechanism analogous to that which occurs in blood, involving complement
fixation by anti-M protein IgG bound to the streptococcal surface and subsequent
phagocytosis by polymorphonuclear leukocytes (16, 17). Our data is consistent with
the idea that opsonic IgG is protective only after streptococcal infection is estab-
lished, and suggests that sIgA alone can protect before the initiation of infection.
Antibody to M protein is defined as type-specific by its ability to opsonize and phagocy-
tize streptococci in whole blood (3). The ability to protect mucosally with sIgA, which
is not opsonic, raises the possibility that antibodies directed to non-type-specific
determinants may be sufficient for initial defense against streptococcal infection .
Studies in progress shall compare the protective ability of sIgA directed to type-
specific and conserved M protein epitopes.
Other investigators have demonstrated that total sIgA derived from immune donors
can passively protect against mucosal infection by bacterial pathogens (18). Perhaps
the most important finding of this passive protection study is that affinity-purified
sIgA protected against infection under conditions whereby serum-derived Ig was
completely ineffective. A clear distinction between sIgA and sera Ig should enable
one to better understand the contribution of antigen-specific sIgA in protection against
mucosal infections. This model might provide greater insight to the effector func-
tions of sIgA and its role in blocking bacterial adherence.
Summary
We present a model in which animals are passively immunized at a mucosal site,
allowing one to evaluate immunological protectionat the mucosal level only. Affinity-
purified, anti-M protein sIgA administered intranasally protected mice against sys-
temic infection after intranasal challenge with group A streptococci. In contrast,
anti-M protein serum Ig administered intranasally was not protective at this site,
although it neutralized the antiphagocytic property of M protein and promoted phago-
cytosis. Protection by sIgA occurred despite the lower immunoreactivity of sIgA
to purified M protein compared with serum Ig. The data suggest that sIgA can pro-
tect at the mucosa and may preclude the need for opsonic IgG in preventing strep-
tococcal infection.
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